[Ergometric dose-effect study of bunitrolol (Stresson) in patients with coronary heart disease (author's transl)].
20 patients with coronary heart disease and ergometrically provocable stenocardias and electrocardiographic signs of ischemia were tested ergometrically with two different dosages (5 mg:20 mg) of the beta-blocking agent bunitrolol (Stresson) in a double-blind-test. The results obtained are in accordance with literature: The greater the ergometric stress the more effective is Stresson and vice versa. For treatment of coronary heart disease can be considered: Low dosage of Stresson in patients with stenocardias and hypoxias in high-grade exercise, high dosage of Stresson in patients with stenocardias or ischemias in low-grade exercise or rest.
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D005082:Physical Exertion; D011412:Propanolamines / Q000627:therapeutic use*
D011412:Propanolamines
Ergometrische Dosis-Wirkungs-Studies mit Bunitrolol (Stresson) bei Patienten mit koronarer Herzkrankheit.